Drawing for -LDL HDL+

USPTO serial 79372661

-LDL HDL+

Reviewed by CopyMark Law Group

Reg. 7518361Status 700Registered
Filing date
Status date
Registration date
Oct 1, 2024
Examiner
AREY, BRANDON LEON
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with -LDL HDL+?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Justin Lampel

Justin Lampel LAMPEL LAW, P.C.555 Skokie Blvd., Suite 500Northbrook, IL 60062United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of hyperlipidemia, atherosclerosis, heart disease, hypertension, cardiometabolic disease, thrombosis and cerebrovascular disease; dietetic food adapted for medical use; dietary supplements for humans; capsules, tablets, powders, and topical preparations of herbs, vitamins, minerals for medicinal use and pharmaceutical purposes for the treatment of hyperlipidemia, atherosclerosis, heart disease, hypertension, cardiometabolic disease, thrombosis and cerebrovascular disease; chemico-pharmaceutical preparations for the treatment of hyperlipidemia, atherosclerosis, heart disease, hypertension, cardiometabolic disease, thrombosis and cerebrovascular disease; liquid herbal and vitamin dietary supplements; dietetic food, namely, dietary and nutritionally fortified food products adapted for medical purposes; food supplements consisting of amino acids, vitamins and trace elements; food supplements, namely, antioxidants; dietetic beverages containing added herbal extracts, vitamins or minerals adapted for medical purposes; pharmaceutical compositions for the treatment of hyperlipidemia, atherosclerosis, heart disease, hypertension, cardiometabolic disease, thrombosis and cerebrovascular disease; pharmaceutical preparations, namely, drug delivery agents in the form of a coating for tablets and capsules that facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical substances for the treatment of hyperlipidemia, atherosclerosis, heart disease, hypertension, cardiometabolic disease, thrombosis and cerebrovascular disease; pharmaceutical preparations, namely, gels for the treatment of hyperlipidemia, atherosclerosis, heart disease, hypertension, cardiometabolic disease, thrombosis and cerebrovascular disease; plant and herb extracts, other than essential oils, for medical purposes; nutritional supplements; healthcare products, namely, medicated toothpaste, medicated shampoo, medicated liquid bath soap; herbal and plant compounds and isolates, other than essential oils, for medicinal purposes; homeopathic pharmaceutical preparations for the treatment of hyperlipidemia, atherosclerosis, heart disease, hypertension, cardiometabolic disease, thrombosis and cerebrovascular disease; medicinal herbs and extracts of medicinal herbs, other than essential oils; medicines based on plant extracts, other than essential oils; natural healthcare preparations, namely, medicated toothpaste, medicated shampoo, medicated liquid bath soap; natural medicinal preparations, namely, medicated toothpaste, medicated shampoo, medicated liquid bath soap; medicinal preparations for the mouth to be applied in the form of tabletsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 19, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 8, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 8, 2025FIMPFINAL DISPOSITION PROCESSED—
Jan 1, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 1, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 1, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 16, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 16, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 16, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 16, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 26, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 21, 2024RNWLINTERNATIONAL REGISTRATION RENEWED—
Jun 7, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 7, 2024XAECEXAMINER'S AMENDMENT ENTERED—
Jun 7, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 7, 2024GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 7, 2024CNEAEXAMINERS AMENDMENT -WRITTEN—
May 27, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 27, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 27, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 29, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 29, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Apr 29, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 29, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 29, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 29, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 8, 2024RFNTREFUSAL PROCESSED BY IB—
Mar 19, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 19, 2024RFRRREFUSAL PROCESSED BY MPU—
Feb 28, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 27, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 20, 2024DOCKASSIGNED TO EXAMINER—
Jun 28, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 24, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 22, 2023SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance